Solid Organ Transplantation Self-Assessment Program (SOTSAP) (Cert # L249252)
ACPE Numbers: Various – see listing below
Release Date: November 15, 2024
Expiration Dates: November 14, 2025
Activity Type: Application-based
CE Credits: 36.5 contact hours (BPS and ACPE)
Activity Fee: $88 (ASHP member); $132 (non-member)
Inaugural Issue
Series Editors Maya Campara, Pharm.D., FCCP, FAST, BCTXP, and Jennifer K. McDermott, Pharm.D., FAST,BCTXP, BCPS and Faculty Panel Chair Lyndsey J. Bowman, Pharm.D., FCCP, FAST, BCPS, BCTXP, shared in a joint statement: As the inaugural issue of SOTSAP, this book not only offers in-depth insights and practical strategies that are essential for optimizing patient care and advancing our field, but also provides 36.5 continuing pharmacy education credits. We believe this book, created by solid organ transplant pharmacists, will be an asset to our practice.
SOTSAP will publish annually in November, with future releases including a minimum of 15.0 credit hours of BCTXP recertification. Topics will vary by issue, but are expected to include the broad subjects of immunosuppression management and monitoring; disease state management; practice management; and case series on specific conditions.
Activity Overview
This course is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 10 learning modules (see table below) and provides up to 36.5 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCTXP recertification approved by the BPS.
Accreditation
 |
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation. |
 |
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education. |
Target Audience
The target audience for Solid Organ Transplant Self-Assessment Program (SOTSAP) Book 1 and is board-certified and advanced level solid organ transplant clinical pharmacists.
Recertification Credit
Board-certified pharmacists are eligible to receive up to 36.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCTXP.
|
Learning Activity |
Passing Score |
Credit Information |
|
Updates in Transplant Outcome Measures and Biomarkers |
66% |
5.0 Contact Hours BPS: BCTXP |
|
Transplant Drug Development and Novel Immunomodulatory Agents |
73% |
4.0 Contact Hours BPS: BCTXP |
|
Diagnosis and Treatment of Antibody-Mediated Rejection |
73% |
3.5 Contact Hours BPS: BCTXP |
| Updates in Cytomegalovirus Management |
73% |
3.5 Contact Hours BPS: BCTXP |
| GI Complications After Solid Organ Transplantation |
73% |
3.0 Contact Hours BPS: BCTXP |
| Peritransplant Antithrombotic Management |
73% |
3.5 Contact Hours BPS: BCTXP |
| Transplant Evaluation Optimization |
80% |
3.5 Contact Hours BPS: BCTXP |
| Pre- and Post Transplant Vaccination |
80% |
3.5 Contact Hours BPS: BCTXP |
| Case Series: Anemia Post-Solid Organ Transplant |
83% |
3.5 Contact Hours BPS: BCTXP |
| Case Series: Management of Neutropenia |
66% |
3.5 Contact Hours BPS: BCTXP |
Learning Objectives
Chapter 1: Updates in Transplant Outcome Measures and Biomarkers
ACPE: 0217-9999-24-241-H01-P
- Evaluate current transplant outcome measures for managing immunosuppressive drugs and important gaps.
- Assess the differences in the available biomarker-based monitoring strategies and analyze the limitations.
- Evaluate the potential role of emerging technology, such as omics-based biomarkers and artificial intelligence, in future immunosuppression management.
Chapter 2: Transplant Drug Development and Novel Immunomodulatory Agents
ACPE: 0217-9999-24-242-H01-P
- Evaluate opportunities and challenges for immunomodulatory drug development after solid organ transplantation.
- Evaluate new roles and novel immunomodulatory agents for induction immunosuppression.
- Assess potential new roles and novel immunomodulatory agents for maintenance immunosuppression.
Chapter 3 Diagnosis and Treatment of Antibody-Mediated Rejection
ACPE: 0217-9999-24-243-H01-P
- Analyze the impact of various assays on diagnosing and monitoring donor-specific antibodies to guide antibody-mediated rejection (AMR) therapy.
- Design a pharmacotherapy plan that considers patient-specific factors for the treatment of AMR.
- Evaluate the current therapies used in desensitization protocols and distinguish the benefits and limitations of each therapy.
Chapter 4: Updates in Cytomegalovirus Management
ACPE: 0217-9999-24-244-H01-P
- Analyze the gaps in current cytomegalovirus (CMV) guidelines as they pertain to drugs and management strategies.
- Assess the differences, benefits, and limitations of available preventive strategies.
- Classify available antiviral treatments and their current role(s) in therapy.
- Evaluate the role of CMV antiviral stewardship, and formulate strategies for clinical practice integration.
Chapter 5: GI Complications After Solid Organ Transplantation
ACPE: 0217-9999-24-245-H01-P
- Assess the risk of different immunosuppressive therapies in causing GI complications after solid organ transplantation, and design a revised immunosuppressive regimen to alleviate these complications.
- Analyze patient risk factors for infectious causes of GI complications, and devise a strategy to decrease patient risks.
- Construct an appropriate treatment strategy on the basis of diagnosis for infectious GI complications.
- Evaluate the relationship between GI complications after solid organ transplantation, the organ transplanted, and patient implications.
Chapter 6: Peritransplant Antithrombotic Management
ACPE: 0217-9999-24-246-H01-P
- Classify common conditions requiring chronic anticoagulation in patients awaiting solid organ transplantation.
- Design a management plan for patients taking oral antithrombotic medications who are listed for solid organ transplantation.
- Construct a protocol designed to standardize the management of reversal agents in patients presenting for solid organ transplantation while taking antithrombotic medications.
- Evaluate the appropriate agents, doses, and timing of postoperative antithrombotic medications based on transplant-specific indications and considerations.
Chapter 7: Transplant Evaluation Optimization
ACPE: 0217-9999-24-247-H01-P
- Distinguish the role of the transplant pharmacist in the pretransplant evaluation visit.
- Evaluate a comprehensive medication review and assess a patient’s adherence status to determine suitability for transplantation.
- Detect nonpharmacologic factors that can affect posttransplant outcomes.
- Assess the impact of pretransplant medications and behaviors on perioperative and posttransplant risks.
Chapter 8: Pre- and Posttransplant Vaccination
ACPE: 0217-9999-24-248-H06-P
- Design an optimal vaccination regimen for organ transplantation candidates and recipients.
- Distinguish vaccination in organ transplantation recipients from the general population, focusing on vaccine efficacy and safety.
- Devise a strategy to complete vaccination given local policies and procedures.
Chapter 9: Case Series: Anemia Post-Solid Organ Transplant
ACPE: 0217-9999-24-249-H01-P
- Evaluate solid organ transplant (SOT) recipients for anemia.
- Assess the patient for dapsone-induced adverse effects.
- Design a management strategy for SOT recipients with human parvovirus B19 infection.
- Distinguish the need for treatment of thrombotic microangiopathy in SOT recipients.
Chapter 10: Case Series: Management of Neutropenia
ACPE: 0217-9999-24-250-H01-P
- Assess solid organ transplant recipients for the presence and severity of neutropenia and evidence-based risk factors.
- Evaluate patients for telomere-related genetic polymorphisms and their significance before and after transplantation.
- Design therapeutic regimens for the prevention and management of neutropenia.
- Analyze the role of granulocyte colony-stimulating factor use in transplant recipients and compare the risk-benefit of their use.
Faculty
Disclosures
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Consultancies: Nicole R. Alvey (Veloxis Pharmaceuticals); Lyndsey Bowman Anger (Veloxis Pharmaceuticals); Steve Gabardi (Merck); Tiffany E. Kaiser (Transplant Genomics); Dana Pierce (Turner Consultation); Lisa Potter (Takeda Pharmaceuticals); David J. Quan (Mallinckrodt Pharmaceuticals); David Salerno (Mallinckrodt; Pfizer); Ashley Anh Vo (Argenx; Hansa Biopharma)
Stock Ownership: Erika Meredith (Abbott; AbbVie); Alexa J. Ray (Vertex Pharmaceuticals; BlueBird Bio)
Grants: Steve Gabardi (Shionogi); Reed Hall (Merck); Margaret R. Jorgenson (Merck); Jennifer Trofe-Clark (Veloxis Pharmaceuticals)
Honoraria: Lyndsey Bowman Anger (Veloxis Pharmaceutica)
Methods and CE Requirements
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Development
ACCP and ASHP collaborate on solid organ transplant pharmacy activities.